Oracle Corporation: Wells Fargo cuts target price to $250 from $280
ORCL•Wells Fargo cut its target price for Oracle to $250 from $280.
Related News
Genmab's petosemtamab-pembrolizumab combination achieves 28.2-month median survival in Phase 2 head and neck cancer trial
GMAB•
Harrow publishes update to financial calendar
HROW•
Coherent Corp.: StoneX initiates coverage with buy rating; target price $425
COHR•
Eni signs key contracts for Cronos gas development in Cyprus
E•
Deutsche Bank raises Palantir Technologies' target price to $225 from $200
PLTR•